Fig. 5

Changes in clinical disability (EDSS) with oral GlcNAc in the combined 6 g and 12 cohorts. A, B Change in EDSS from baseline (average of V1 and V4) after 4 weeks of GlcNAc (visit 8) or 4 weeks after stopping GlcNAc (visit 11) in the intention to treat (A) and per protocol (B) groups. C, D Number of subjects with 4-week confirmed improvement or worsening of EDSS after 4 weeks of GlcNAc (visit 8) determined by comparing change from baseline (average of visits 1 and 4) to visit 8 that was confirmed 4 weeks later at visit 11 in the intention to treat (C) and per protocol (D) groups. Error bars represent SEM. P value by one-tailed Wilcoxon paired t test (A, B) or binomial test (C, D)